Quick Answer
Neurogene Inc. reported Research And Development Expense of $75.01 million for the year ending 2025.
- Neurogene Inc. showed an increase of +23.1% in Research And Development Expense from 2024 to 2025.
- This data is from Neurogene Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2026.
- XBRL data for this metric is available from 2012 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2012 to 2025), Neurogene Inc.'s Research And Development Expense has grown by 1,140.8%.
- Historical annual values: Fiscal year 2025: $75.01 million | Fiscal year 2024: $60.92 million | Fiscal year 2023: $44.39 million | Fiscal year 2022: $47.51 million | Fiscal year 2021: $39.16 million | Fiscal year 2018: $41.79 million | Fiscal year 2017: $36.27 million | Fiscal year 2016: $28.38 million | Fiscal year 2015: $15.80 million | Fiscal year 2014: $18.08 million | Fiscal year 2013: $7.60 million | Fiscal year 2012: $6.05 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: